This protocol applies to patients with growth hormone deficiency who have an active malignancy. The concurrent oncological condition is a decisive factor in the clinical decision-making pathway for GHD management.
Evidence-based guidelines specify a clear recommendation regarding growth hormone therapy when active malignancy is present. The full structured protocol sets out this recommendation with its supporting evidence and grading.